“For patients who are taking current standard-of-care #anticoagulants to mitigate their risk of #stroke, it can be frightening to have to stop taking treatment – even temporarily – to undergo any procedure.” - Mellanie True Hills, CSP, Founder and CEO of StopAfib.org. A new analysis from the AZALEA-TIMI 71 study just presented at the European Society of Cardiology (ESC) Congress by Dr. Siddharth Patel from the TIMI Study Group, demonstrated that abelacimab was associated with very low levels of periprocedural bleeding in patients with #atrialfibrillation. Read the press release in full: https://bit.ly/3z0MiaO. #ESCCongress #FactorXI #atrialfibrillation #afib #afibawareness #stroke #strokeawareness #thrombosis #hemostasis
Anthos Therapeutics
Biotechnology Research
Cambridge, Massachusetts 3,694 followers
Anthos Therapeutics is a clinical-stage biopharma company developing innovative therapies for cardiovascular patients.
About us
Anthos Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of genetically and pharmacologically validated innovative therapies to advance care for people living with cardiovascular and metabolic (CVM) diseases. Anthos Therapeutics aims to combine the agility of a biotech with the rigor of a large pharmaceutical company. Anthos Therapeutics was launched by Blackstone Life Sciences in 2019.
- Website
-
http://www.anthostherapeutics.com
External link for Anthos Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Privately Held
Locations
-
Primary
55 Cambridge Pkwy
103
Cambridge, Massachusetts 02142, US
Employees at Anthos Therapeutics
Updates
-
#NEWS: #AnthosTherapeutics announced today, at a late-breaking session of the European Society of Cardiology (ESC) Congress, a new analysis from the landmark AZALEA-TIMI 71, demonstrating that abelacimab was associated with very low levels of periprocedural bleeding in patients with #atrialfibrillation. The new analysis presented by Dr. Siddharth Patel from the TIMI Study Group found that approximately 1% of patients taking abelacimab experienced a major or clinically relevant non-major (CRNM) bleed while undergoing a procedure. This data further substantiates the growing body of evidence supporting the safety profile of abelacimab, a novel once-monthly administered, highly selective, fully human monoclonal antibody currently being studied in Phase 3 trials. Read the press release in full: https://bit.ly/3z0MiaO. #ESCCongress #FactorXI #atrialfibrillation #afib #afibawareness #stroke #strokeawareness #thrombosis #hemostasis
-
Dr. Siddharth Patel from the TIMI Study Group will present periprocedural data from the landmark AZALEA-TIMI 71 #atrialfiibrillation study as a late-breaker at the European Society of Cardiology (ESC) Congress 2024. Save the date! Check out the #ESCCongress late-breaker program here 👉: https://bit.ly/3WUUDVe. #afib #afibawareness #strokeawareness #FactorXI #FactorXIa #thrombosis #hemostasis #anticoagulant #anticoagulation #abelacimab #AnthosTherapeutics
-
Will #FactorXI inhibitors replace current #anticoagulants for #stroke prevention in #atrialfibrillation? To learn more about what may be possible, read the latest article from Drs. Siddharth Patel and Christian Ruff from the TIMI Study Group to get the latest news 👉: https://bit.ly/3T7qa58. Stay tuned for an exciting new analysis from the AZALEA-TIMI 71 Study being presented as a late-breaker at the European Society of Cardiology (ESC) Congress 2024 on Monday, September 2nd, at 10:15 AM ET. #ESCCongress #afib #afibawareness #stroke #strokeawareness #thrombosis #hemostasis
-
#AnthosTherapeutics is headed to London for the European Society of Cardiology (ESC) Congress 2024. Periprocedural data from the AZALEA-TIMI 71 study will be unveiled on Monday, September 2nd, at 10:15 AM ET. Presented by Dr. Siddharth Patel from the TIMI Study Group, these important data further support the increasing body of evidence for abelacimab as a promising #FactorXI inhibitor. Stay tuned for more exciting updates. Check out the congress program here: https://bit.ly/3WUUDVe. #ESCCongress #atrialfibrillation #afib #afibawareness #stroke #strokeawareness #thrombosis #hemostasis
-
Join the #AnthosTherapeutics team! We're hiring a hybrid Director of Program Management. Please send qualified resumes to Gi Gi Galiano - [email protected]. Check out the job description below. 👇 #hiring #careers
-
Anthos Therapeutics looks forward to attending the fast-approaching Get in Rhythm, Stay in Rhythm #AtrialFibrillation Patient Conference from August 9th to 11th. The dedicated StopAfib.org team expertly organizes this annual event, which brings together patients, healthcare practitioners and experts to share information in a friendly and accessible manner. Don’t miss out on attending this inspiring event in person or virtually. Learn more and register here: https://getinrhythm.com/. #atrialfibrillation #afib #afibawareness #stroke #strokeawareness #thrombosis #hemostasis #FactorXI
-
#FactorXI inhibitors hold promise for safer #anticoagulants, potentially offering #stroke protection without severe bleeding risks. This innovation could bring peace of mind to patients and benefit those at high bleeding risk. How might this be achieved? Factor XI inhibitors specifically target the pathological #thrombosis pathway, leaving the physiological #hemostasis pathway unaffected. Learn more about the potential of the emerging class of Factor XI from a recent article published in The Wall Street Journal: https://bit.ly/3Twwh2C. #atrialfibrillation #afib #afibawareness #stroke #strokeawareness #venousthromboembolism #cancerassociatedthrombosis #thrombosis #hemostasis #FactorXI
WSJ | New Blood Thinners Will Prevent Blood Clots Without Causing Bleeding
webreprints.djreprints.com
-
#FactFriday: Nearly one in every six strokes is caused by #afib, and these strokes can be twice as fatal as those unrelated to the condition. Learn more about #afib and #stroke from our friends at the National Blood Clot Alliance: https://bit.ly/3UFhEKx. #atrialfibrillation #afib #afibawareness #stroke #strokeawareness #thrombosis #hemostais #stoptheclot #FactorXI #FactorXIa
-
#AnthosTherapeutics wishes everyone a safe and healthy #FourthofJuly. Let us celebrate this #IndependenceDay with gratitude for the freedoms we all enjoy. #July4th